Biologics Drug Discovery2024-02-14T14:52:46-05:00

Biologics Drug Discovery.

Comprehensive Biologics Drug Discovery Pipeline: From Discovery to Lead Selection and Characterization.

Biologic drugs have a high degree of complexity compared to their small molecule counterparts and require a comprehensive and analytical approach for lead selection and characterization. While several technologies exist for generating hits, many biologics drug discovery pipelines are challenged with effectively selecting and engineering candidates to ensure functionality, specificity, optimal performance, and developability.

The integration of artificial intelligence (AI) guided de novo antibody sequencing, SPR, and HDX-MS make it possible to accelerate the biologics discovery and development workflow. Additionally, REpAb antibody discovery offers a short-cut to optimized, functional mAbs by extracting amino acid sequences directly from serum. Advanced epitope mapping and binning technology focuses discovery and engineering efforts on the most important candidates.

Services for Biologics Drug Discovery.

We facilitate the biologics drug discovery and validation pipeline, offering seamless integration from the discovery phases to lead selection. Gain direct access to the amino acid sequence and comprehensive characterization throughout the process.

Antibody Sequencing & Discovery Services.

Antibody Discovery with Polyclonal Antibody Sequencing

Explore the entire antibody repertoire and uncover physiologically relevant, novel binders directly from the immunoserum.

Explore REpAb

De Novo Monoclonal Antibody Sequencing

Identify and validate targets for biologics discovery. Extract the CDR sequences to add to your framework or discovery platform to facilitate future engineering.

Explore REmAb

Binding Kinetics

Measure key antibody properties (ie. binding affinity, specificity, kinetics) to screen and identify lead candidates with optimal therapeutic potential.

Explore SPR Binding Kinetics

Epitope Mapping

Identify linear, conformational, and structural epitopes to unveil the antibody’s binding paratope. Investigate binding epitopes and elucidate the therapeutic mechanism of action.

Explore HDX-MS Epitope Mapping

Glycan Analysis

Characterize the glycan profile and pinpoint glycosylation sites that may influence antibody functions, tailoring them for specific therapeutic purposes in leading candidates.

Explore GLYscan

Sequence Confirmation

Validate protein sequences during protein after protein expressions and during cell line development. Minimize troubleshooting with rapid and real-time peptide mapping.

Explore MATCHmAb

“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”

Pavel Khrimian – Co-founder and CBO, Deka Biosciences

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.